SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences, Inc., (“Apricus Bio”) (Nasdaq: APRI) today announced the award of three grants totaling $733,437 under the Qualifying Therapeutic Discovery Project program for PrevOncoTM, RayVaTM and Femprox® which are the Company’s development programs in cancer, autoimmune/cardiovascular and female sexual dysfunction, respectively. The credit is a tax benefit for 2010 expenditures awarded to therapeutic discovery projects that show a reasonable potential to result in new therapies that treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions. Apricus Bio will use the proceeds of the grant funds to continue development of PrevOnco™, RayVa™ and Femprox®.
